Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy

Tampellini, Marco; Ottone, Azzurra; Alabiso, Irene; Baratelli, Chiara; Bitossi, Raffaella; Brizzi, Maria Pia; Leone, Francesco; Forti, L.; Bertona, E.; Racca, Patrizia; Mecca, C.; Alabiso, Oscar; Berruti, Alfredo; Scagliotti, Giorgio V.

doi:10.1093/annonc/mdv340.28

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To the best of our knowledge, none of these studies were related to chemotherapy for MCRPC. In an Italian analysis of first-line chemotherapy in 1610 newly diagnosed patients with metastatic colorectal cancer, a strong circannual rhythm in response rate was evident, with the higher proportion of responding patients in the subgroup diagnosed in January [17]. Moreover, a circannual rhythmicity of the proportion of patients progressing at 6 months and surviving at 1 year was demonstrated, with acrophases located both in winter (February and January, respectively).…”

Section: Discussionmentioning

confidence: 99%

Is there a seasonal variation of survival after systemic chemotherapy for metastatic castration-resistant prostate cancer in a rural part of North Norway?

Nieder

Dalhaug

Haukland

2020

International Journal of Circumpolar Health

View full text Add to dashboard Cite

The winter darkness or polar night induces endocrine and metabolic mechanisms, which might reduce the efficacy of cancer treatment and thus contribute to shorter survival. Moreover, seasonand weather-related treatment delays and irregularities might also cause reduced efficacy of anticancer drugs. Therefore, this study evaluated the prognostic impact of timing of chemotherapy (start during winter darkness or outside of this season), in terms of overall survival, in patients with metastatic castration-resistant prostate cancer (MCRPC) who received oncology care at the Nordland hospital Bodø. The study included 111 patients treated with first-line docetaxel chemotherapy for MCRPC. Twenty patients (18%) started their treatment during winter darkness (arbitrarily defined as ±4 weeks around 21 December). In unadjusted univariate analysis, survival was shorter in this group (median 10.2 vs. 18.9 months, p = 0.055). However, not all baseline parameters were equally distributed between the two groups. In multivariable-adjusted Cox regression analysis accounting for several confounding variables, only one factor was statistically significant: pre-chemotherapy serum lactate dehydrogenase level (a surrogate marker of disease burden). Thus, the present results suggest that seasonal variation is not a major contributor to the diverging survival outcomes observed after docetaxel chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%